A B ‐Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies

ConclusionThe BRAF signature may better help guide targeted therapy for melanoma, and such a framework can be applied to other cancers and mutations to provide more information than mutation status alone.

Source: Cancer Medicine - January 19, 2022 Category: Cancer & Oncology Authors: Kevin Yao, Emily Zhou, Chao Cheng Tags: RESEARCH ARTICLE Source Type: research